'%3e%3cpath%20d='M34.1406%205.85938C30.3906%202.10547%2025.3047%200%2020%200C14.6953%200%209.60938%202.10547%205.85938%205.85938C2.10938%209.61328%200%2014.6953%200%2020C0%2025.3047%202.10547%2030.3906%205.85938%2034.1406C9.61328%2037.8906%2014.6953%2040%2020%2040C25.3047%2040%2030.3906%2037.8945%2034.1406%2034.1406C37.8906%2030.3906%2040%2025.3047%2040%2020C40%2014.6953%2037.8945%209.60938%2034.1406%205.85938ZM37.0117%2023.543H31.1602V13.5391H27.6328V19.9414C28.1211%2020.6914%2028.3711%2021.582%2028.3711%2022.5625V22.625C28.3711%2023.668%2028.1172%2024.6055%2027.6328%2025.4297V26.6094H36.082C33.4883%2032.9375%2027.2891%2037.3789%2020.0039%2037.3789C10.3711%2037.3789%202.62109%2029.6289%202.62109%2020C2.62109%2010.3711%2010.3711%202.62109%2020%202.62109C29.6289%202.62109%2037.3789%2010.3711%2037.3789%2020C37.3789%2021.1484%2037.2617%2022.2656%2037.0508%2023.3477C37.0391%2023.4141%2037.0234%2023.4766%2037.0117%2023.543Z'%20fill='white'/%3e%3cpath%20d='M22.3086%2018.5352C20.4336%2018.125%2019.9531%2017.8398%2019.9766%2017.1836V17.1406C19.9766%2016.6992%2020.3477%2016.2148%2021.4023%2016.2148C22.582%2016.2148%2023.8867%2016.6797%2025.0781%2017.4766L26.8516%2015.0195C25.4453%2013.8906%2023.707%2013.3398%2021.5547%2013.3398C18.5195%2013.3398%2016.4375%2015%2016.4063%2017.4766V17.5352C16.3633%2020.2617%2018.5859%2020.9805%2021.293%2021.6016C23.0391%2021.9766%2023.5703%2022.3164%2023.5703%2022.9609L23.5469%2022.9766C23.5469%2023.3906%2023.2578%2023.7031%2022.7852%2023.8359C22.5742%2023.9062%2022.1289%2023.9727%2021.5156%2023.9727C20.7617%2023.9727%2019.7539%2023.8633%2018.6328%2023.4844C18.0898%2023.2891%2017.4727%2023.0039%2016.8047%2022.6133L20.1406%2026.625C20.2813%2026.6602%2021.0977%2026.8516%2021.7734%2026.8516C25.0039%2026.8516%2027.0859%2025.2461%2027.1094%2022.6328V22.5703C27.1602%2020.1133%2025.2148%2019.1719%2022.3086%2018.5352Z'%20fill='white'/%3e%3cpath%20d='M5.24219%2013.5664V26.6133H8.75391V23.7578L10.2969%2021.9531L14.2031%2026.6133H18.3867L12.3555%2019.5195L17.4023%2013.5664H13.4531L8.75391%2019.0586V13.5664H5.24219Z'%20fill='white'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_97_2430'%3e%3crect%20width='40'%20height='40'%20fill='white'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)
Lifestyle Features
Most Recent
$80K bronze statue of Kentucky Derby winner stolen in Sacramento
Madisen Keavy, KVOR via CNN | Updated Oct. 2 - 11:49 a.m. | Save Story
A nearly 7-foot bronze statue honoring a Kentucky Derby winner has been stolen from Sacramento's Del Paso Boulevard, leaving a community without a piece of its history.
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
Bhanvi Satija, Reuters | Updated Oct. 2 - 8:08 a.m. | Save Story
Chinese biotech company Abogen said on Friday it has signed a licensing deal worth up to $7.8 billion with Novartis to develop messenger RNA-based therapies, underscoring the Swiss drugmaker's growing focus on an emerging class of treatments.
Arkansas gem hunter finds a diamond he claims could be worth $1M
Laura Turbay, Report For America, Associated Press | Updated Oct. 2 - 7:41 a.m. | Save Story
Jack Pearadin dug up a large diamond, now known as the "American Dream," in August, and collectors believe the rock could now be worth up to $1 million.
5-year-old may be youngest to ever DJ a music festival
VideoAlex Cabrero, KSL | Updated Oct. 2 - 6:17 a.m. | Save Story
While most 5-year-olds are still working on their ABCs, Hadley Lovell is already working on her BPMs (beats per minute).
Zealand Pharma slides as concerns over patients quitting survodutide trials resurface
Reuters | Updated Oct. 1 - 2:44 p.m. | Save Story
Nearly one in five patients quit Zealand Pharma's late-stage survodutide trial due to gastrointestinal side effects caused by the obesity drug, data released on Thursday showed, again raising investor concerns over the high dropout rates.
Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute
Bhanvi Satija and Mariam Sunny, Reuters | Updated Oct. 1 - 11:21 a.m. | Save Story
Sanofi and Regeneron said on Thursday they will develop four new drugs together in a deal worth up to $8 billion and settle prior litigation, moves analysts said signal a reset of their strained partnership and an early win for the French drugmaker's new CEO Belen Garijo.
In the kitchen, Gabby finds joy after years in foster care
VideoAshley Moser, KSL | Updated Oct. 1 - 10:24 a.m. | Save Story
Sixteen-year-old Gabby, who has lived in five foster homes, finds comfort in cooking and hopes to find a caring family to call her own.
MSF staff member tests positive for Ebola in Congo, aid organisation says
Reuters | Updated Oct. 1 - 8:12 a.m. | Save Story
A Médecins Sans Frontières staff member working on the Ebola response in the Democratic Republic of Congo has contracted the Ebola Bundibugyo virus and is being evacuated to the Netherlands for treatment, the humanitarian organisation said on Thursday.
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial
Sriparna Roy, Reuters | Updated Oct. 1 - 7:51 a.m. | Save Story
An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone in a study of patients with obesity, according to data being presented at a medical meeting.
Bangladesh warns dengue outbreak could worsen after deadly September
Ruma Paul, Reuters | Posted Oct. 1 - 1:45 a.m. | Save Story
Bangladesh enters October facing a worsening dengue outbreak after its deadliest month this year, as experts warned that weather conditions could fuel further spread, piling pressure on hospitals already fighting the world's worst measles outbreak.
Experimental Lilly combination drug tops Zepbound in weight-loss trial
Patrick Wingrove, Reuters | Updated Sept. 30 - 2:30 p.m. | Save Story
Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its blockbuster Zepbound in a head-to-head trial, intensifying the competition with Danish rival Novo Nordisk for new, more effective obesity therapies.
Walgreens-owner Sycamore nears $9 billion sale of Boots, WSJ reports
Reuters | Updated Sept. 30 - 2:14 p.m. | Save Story
Walgreens-owner Sycamore Partners is close to a deal to sell British pharmacy chain Boots to the Weston family for about $9 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Merck's experimental skin disease drug succeeds in mid-stage study
Sahil Pandey, Reuters | Updated Sept. 30 - 9:22 a.m. | Save Story
Merck said on Wednesday its experimental drug significantly reduced inflammatory skin lesions in patients with a chronic skin disease, meeting the main goal of a mid-stage study.
Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
Reuters | Updated Sept. 30 - 8:45 a.m. | Save Story
The weight-loss drug market is booming, with biotech firms racing to capture a slice of the fast-growing sector dominated by Novo Nordisk and Eli Lilly.
Cigna expects $3 billion in cost savings by 2030
Reuters | Updated Sept. 30 - 8:40 a.m. | Save Story
(Corrects headline and paragraph 1 to clarify that Cigna is not investing $3 billion, but expecting that amount in cost savings by 2030)
Factbox-Major drugmakers turn to China for licensing deals
Reuters | Updated Sept. 30 - 6:17 a.m. | Save Story
Novo Nordisk said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-developed medicines.
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
Patrick Wingrove, Reuters | Updated Sept. 30 - 3:57 a.m. | Save Story
Patients who switched from weight-loss injections to Novo Nordisk's daily Wegovy pill continued to lose weight, according to data unveiled at a medical meeting on Wednesday, as the Danish drugmaker seeks to defend its lead over US rival Eli Lilly in the market for oral obesity treatments.
Gerresheimer's quarterly sales recovery boosts shares
Reuters | Updated Sept. 30 - 2:01 a.m. | Save Story
Gerresheimer reported a sequential recovery in its second-quarter revenue on Wednesday, sending its shares 8% higher in early trading, as demand for its drug delivery devices boosted sales.
